Virtu Financial LLC Makes New $102,000 Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Virtu Financial LLC purchased a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,033 shares of the company’s stock, valued at approximately $102,000.

Several other hedge funds have also made changes to their positions in the company. nVerses Capital LLC grew its position in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of iTeos Therapeutics during the third quarter valued at $31,000. China Universal Asset Management Co. Ltd. raised its position in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after buying an additional 2,646 shares during the period. Quest Partners LLC lifted its stake in iTeos Therapeutics by 914.7% in the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after acquiring an additional 690 shares during the period. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Insider Buying and Selling

In related news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ITOS. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Thursday, December 12th. Wells Fargo & Company dropped their price objective on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday, December 13th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock opened at $7.22 on Friday. The firm has a market cap of $263.78 million, a price-to-earnings ratio of -2.29 and a beta of 1.37. The stock has a 50-day simple moving average of $8.59 and a 200-day simple moving average of $12.71. iTeos Therapeutics, Inc. has a 52-week low of $7.12 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities research analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.